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Human osteoclastMetal-on-metal hip replacement (MOMHR) using large diameter bearings has become a popular alternative to
conventional total hip arthroplasty, but is associated with elevated local tissue and circulating levels of chromium
(Cr) and cobalt (Co) ions that may affect bone health. We examined the effects of acute and chronic exposure to
these metals on human osteoblast and osteoclast formation and function over a clinically relevant concentration
range previously reported in serum and within hip synovial ﬂuid in patients after MOMHR. SaOS-2 cells were
culturedwith Co2+, Cr3+ and Cr6+ for 3 days after which anMTS assay was used to assess cell viability, for 13 days
after which alkaline phosphatase and cell viabilitywere assessed and for 21 days afterwhich nodule formationwas
assessed. Monocyteswere isolated from human peripheral blood and settled onto dentine disks then culturedwith
M-CSF and RANKL plus either Co2+, Cr3+ or Cr6+ ions for 21 days fromday 0 or between days 14 and 21. Cellswere
ﬁxed and stained for TRAP and osteoclast number and amount of resorption per dentine disk determined. Co2+ and
Cr3+ did not affect osteoblast survival or function over the clinically equivalent concentration range, whilst Cr6+
reduced osteoblast survival and function at concentrations within the clinically equivalent serum range after
MOMHR(IC50=2.2 μM). In contrast, osteoclastsweremore sensitive tometal ions exposure. At serum levels amild
stimulatory effect on resorption in forming osteoclasts was found for Co2+ and Cr3+, whilst at higher serum and
synovial equivalent concentrations, and with Cr6+, a reduction in cell number and resorption was observed. Co2+
and Cr6+within the clinical range reduced cell number and resorption inmature osteoclasts. Our data suggest that
metal ions at equivalent concentrations to those found inMOMHR affect bone cell health andmay contribute to the
observed bone-related complications of these prostheses.rch Unit for Musculoskeletal
neral Hospital, Herries Road,
ilkinson).
-NC-ND license.© 2011 Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
In recent years total hip replacement using large diameter metal-on-
metal bearings (MOMHR), either as a hip resurfacing procedure or using a
stemmed femoral prosthesis, has become a common alternative to
conventional total hip arthroplasty (THA) for the treatment of young and
active arthritis patients because of advantages of lower volumetric wear
anddislocation risk [1].However, theclinical outcomesofhip replacement
using these prostheses have been mixed. Data from the National Joint
Register for England and Wales (2008) demonstrated a 3-year revision
rate for hip resurfacing of 4.4% (95%CI 4.0 to 5.0) compared with 1.3%
(1.2 to 1.4) for cemented THA (www.njrcentre.org.uk). The Australian
Arthroplasty Register (1997 to 2005) also reported a higher 3-yearrevision rate for hip resurfacing versus THA (3.1% (2.7 to 3.6) versus 2.1%
(1.9 to 2.5%) www.dmac.adelaide.edu.au/aoanjrr). The most common
adverse events necessitating revision surgery after MOMHR include early
periprosthetic fracture, osteolysis, failure of prosthesis osseo-integration
resulting in aseptic loosening, unexplained pain, and inﬂammatory
masses [2–7].
Circulating physiological levels of cobalt and chromium are normally
b0.25 μg/L (0.005 μM). Elevated levels of cobalt and chromium occur in
both the hip synovialﬂuid and in peripheral blood afterMOMHR.Whole
blood concentrations of cobalt and chromium after MOMHR of up to
4.6 μM and 2.3 μM, respectively [8], and local hip synovial ﬂuid levels of
up to 30 μM and 25 μM, respectively, have been measured in-vivo [9].
Whilst circulating metal levels are usually highest over the ﬁrst few
months after implantation, persistent elevation occurs as late as 10 years
after surgery [10].
Previous studies have shown that short-term exposure to these
metal species may affect human osteoclast and osteoblast survival and
function. High concentrations of cobalt2+ (Co2+), chromium3+ (Cr3+),
and chromium6+ (Cr6+) ions is toxic to osteoblasts and reduces cell
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chromium exposure on primary human osteoclasts, although Nichols
and Puleo showed short-term exposure to Co and Cr ions at sub-lethal
doses resulted in decreased resorptive activity in rat osteoclasts [14]. In
contrast, Rousselle et al. foundexposure of rabbit osteoclasts to Cr3+had
no effect on rabbit osteoclast function [15]. Sankaramanivel et al. have
shown that rats treated intraperitoneally with potassium dichromate
(Cr6+) over 5 days led to accumulation of chromium in the femur, and
was associated with reduced systemic assays of alkaline phosphatase
and tartrate-resistant acid phosphatase, suggesting an impact on both
bone formation and resorption [16]. However, the longer-term effect of
chronic exposure of both human osteoblasts and osteoclasts to these
ions at clinically relevant concentrations, more akin to clinical exposure
both systemically and at the level of the hip joint, is unknown.
Wehypothesise that chronic exposure of local bone cells tometal ions
may contribute to the clinical bone-related complications after MOMHR.
The aims of this study were to investigate the effect of both short-term
and chronic Co2+, Cr3+, and Cr6+ ion exposure at clinically relevant
concentrations after MOMHR on human osteoblast and osteoclast
proliferation and function, and on mature primary human osteoclasts.
A dose-ranging methodology was used including metal ion levels
covering the normal physiological range, through systemic levels found
after MOMHR, to the high concentrations reported in hip joint synovial
ﬂuid aspirates after MOMHR.
Materials and methods
Metal ion preparation and validation of concentrations
Co2+ and Cr3+ were purchased as cobalt (II) chloride hexahydrate
and Chromium (III) chloride hexahydrate from Sigma-Aldrich Company
Ltd, Gillingham, UK. Cr6+ was purchased as chromium (VI) oxide from
BDH, Lutterworth, UK. Stock solution for each metal ion at 0.2 M was
prepared in 50 ml of sterile water and stored at 4 °C prior to use. The
0.2 M stock solutions were serially diluted in sterile distilled water to
give aliquots of 100X theworking concentration range for the treatment
of cells. These were then diluted in Dulbecco's modiﬁed Eagle's medium
(DMEM©GLUTAMAX™) supplementedwith0.5% FCSand1%penicillin–
streptomycin (10000units penicillin, 10,000 μg/ml streptomycin),which
from here on will be referred to as vehicle. Control treatments were
prepared to contain 1% of distilled sterile water in vehicle to maintain
conditions, referred to as 0 μM treatments.
Theﬁnalmetal ion concentrations in the test solutionswere conﬁrmed
using ﬂame-atomic absorbance spectroscopy. Co2+, Cr3+ and Cr6+
predictedversusmeasuredconcentrationshowedcloseagreement (linear
regression, r2=1.00, 0.85 and0.98 for Co2+, Cr3+ andCr6+, respectively).
Osteoblast cell culture
Human SaOS-2 cells (a human osteosarcoma-derived osteoblast cell
line) were cultured in T75 ﬂasks containing Dulbecco's modiﬁed Eagle's
medium (DMEM© Glutamax™, Gibco® Invitrogen, Paisley, UK) supple-
mented with 10% FCS, 100 IU/mL of penicillin and 100 μg/mL of
streptomycin (Sigma, Poole, UK), hereafter termed complete DMEM.
The cellsweremaintained at 37 °C in a humidiﬁed atmosphere of 95% air
and 5% CO2 until required for assay.
Osteoblast viability and proliferation
SaOS-2 cellswere seeded into96-well plates at 5×103 cells perwell in
0.1 mL of complete DMEM and left to adhere overnight. The medium
was then replaced with DMEM supplemented with 0.5% FCS and
100 IU/mL of penicillin and 100 μg/mL of streptomycin (referred hereon
in as vehicle)±metal ion treatments and incubated for 3 or 13 days
at 37 °C in a humidiﬁed atmosphere of 95% air and 5% CO2. Vehicle±
treatmentswere replenishedevery3rdand4thdayconsecutively for cellscultured for 13 days. At the end of the culture period a CellTiter 96®
AQueous Non-Radioactive Cell Proliferation Assay was performed accord-
ing to the manufacturer's instructions (Promega, Southampton, UK). The
assay utilises dehydrogenase enzymes found in metabolically active cells
to convert 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) into an aqueous
soluble formazan product. The absorbance of the formazan product
produced by the cells was read at 490 nm using a SpectraMax M5e
Microplate Reader (Molecular Devices, Sunnyvale, CA). Values were
expressed as percentage response relative to vehicle.
Osteoblast synthetic function
Alkaline phosphatase (ALP) activity
SaOS-2 cells were seeded into 24-well plates at 15×103 cells per
well in 1 mL of complete DMEM, left to adhere overnight and then
the medium was replaced with vehicle±metal ion treatments and
incubated for 13 days at 37 °C in a humidiﬁed atmosphere of 95% air
and 5% CO2. The vehicle±treatments were replenished every 3rd or
4th day. Cells were washed with PBS, lysed in nuclease-free water and
frozen at −80 °C following completion of culture. Cell lysates were
obtained after three freeze and thaw cycles. ALP activity was measured
using p-nitrophenyl phosphate (pNPP) (Sigma) as the chromogenic ALP
substrate in the presence of Mg2+ ions in a buffered solution. The
absorbance was read at 405 nm using a SpectraMax M5e Microplate
Reader. Values were expressed as percentage response relative to
vehicle. DNA contentwas quantiﬁed usingQuant-iT™ PicoGreendsDNA
Assay Kit (Invitrogen, Paisley, UK) according to the manufacturer's
instructions. ALP activity was normalised to DNA content and ALP/DNA
was then expressed as percentage response relative to vehicle.
Osteoblast mineralisation
Once the SaOS-2 cells had reached conﬂuency the cells were treated
with vehicle supplemented with 10-8 M dexamethasone and 50 μg/ml
ascorbic acid (referred to as osteogenicmedium)±metal ion treatment.
Metal ion treatments in osteogenic mediumwere changed every 3rd or
4th day. Two days prior to experiment end, 10 μL of 5 mM inorganic
phosphate 4.2pHwasadded to the existing treatmentswithin eachwell.
On day 21 cells were then washed once in PBS, ﬁxed in 100% ethanol,
rinsed in PBS and incubated in 40 mM alizarin red (pH 4.2; Sigma) for
1 hour at room temperature. The cells were then washed extensively in
95% ethanol and air-dried. The plateswere scanned on a high-resolution
ﬂat-bed scanner. The percentage of each well stained with alizarin red
was quantiﬁed using Image J software (NIH: http://rsb.info.nih.gov/ij/)
and expressed as percentage response relative to vehicle.
Human osteoclast culture
Osteoclasts were generated from human peripheral bloodmonocytes
taken from healthy volunteers as previously described andwith research
ethics committee approval [17]. Sterilisation of 6 mmdiameter coverslips
(Richardson's of Leicester, Leicester,UK)wasperformedbybaking at 180°
for 2 hours. Dentine disks (www.dentinedisks.com) were sonicated and
sterilised by washing in 70% ethanol overnight. Venous blood was
obtained from healthy volunteers and separated using Histopaque®-
1077 (Sigma). Themonocyte fractionwas collected, washed and then re-
suspended in α-MEM Glutamax (Gibco® Invitrogen, Paisley, UK). An
appropriate volume of cell suspension containing 5×105 cells was then
added to pre-wetted coverslips or dentine disks in a 96-well plate. Cells
were incubated for a minimum of 1 hour to allow adherence to the
dentine or glass surface. Non-adherent cells were subsequently washed
away with α-MEM. Adherent cells were incubated in 100 μL α-MEM
Glutamax containing 10% FCS, 100 U/mL penicillin, 100 μg/mL strepto-
mycin (Sigma) (referred to as completeα -MEM)andsupplementedwith
25 ng/mLM-CSF, 30 ng/mL recombinant RANKL (Insight Biotechnology,
Wembley, UK) at 37 °C in a humidiﬁed atmosphere of 93% air and 7% CO2
Fig. 1. Effect ofmetal ions onosteoblast viability. SaOS-2 cellswere culturedwith clinically
relevant levels of Co2+, Cr3+ and Cr6+ for 3 days after which time a MTS assay was used
to assess cell viability. All values expressed relative to vehicle (100%). n=6 wells per
experiment, 3 replicate experiments. Values are mean±SEM. Arrows represent upper
limit of previously reported ion concentrations in-vivo.
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treatmentswere added fromday 3,whilst for effects onmature osteoclast
activity metal ion treatments were added after the onset of resorption
(typically 14 days). Complete α-MEM containing 25 ng/mL M-CSF,
30 ng/mL RANKL and treatments was replaced every 2–3 days.
TRAP staining
Dentine disks were TRAP stained as previously described [18,19].
Brieﬂy, the disks were ﬁxed in 10% buffered formalin. Disks were then
incubated in pre-warmed Acetate-tartrate buffer (0.1 M Sodium tartrate
(Sigma) in 0.2 M Acetate buffer (Sigma), pH 5.2) at 37 °C for 5 min,
followed by 30 min incubation at 37 °C in 20 mg/mL Naphthol AS-BI
phosphate (Sigma)/dimethylformamide (Fisher Scientiﬁc, Loughborough,
UK) in acetate-tartrate buffer. The disks were then incubated in acetate-
tartrate buffer hexazotised pararosaniline solution. The disks were rinsed
in water and counterstained in Gill's haematoxylin.
Quantiﬁcation of osteoclast number and resorption
Resorbing osteoclasts were identiﬁed on dentine disks as a TRAP
positive cell in or in close proximity to resorptionpits andquantiﬁed from
8 random ﬁelds of view per disk. Resorption lacunae were identiﬁed in
the same 8 random ﬁelds of view per disk and the plan area of resorption
wasdeterminedbypoint counting as previouslydescribed [20]. All values
were expressed as percentage response relative to vehicle.
Statistical analysis
All treatment comparisonsweremade versus vehicle (0 μM). Logistic
curve ﬁtting was performed using the least squares (ordinary ﬁt)
method and a standard Hill slope to calculate IC50 values where effects
on bone cell proliferation were found. Data sets were analysed using
ANOVA with Dunnett's multiple comparison post-test or the Kruskal–
Wallis testwithDunn'smultiple comparison post-test, depending on the
normality of the data distribution. All analyses were conducted 2-tailed
using a critical p-value of 0.05 using GraphPad Prism® (GraphPad
Software, La Jolla, CA).
Results
Effect of short-term exposure to metal ions on osteoblast viability
Treatment up to 2000 μM of all ions caused a reduction in the
number of viable, metabolically active osteoblasts compared to vehicle
after 3 days (Fig. 1, ANOVA pb0.0001). Cr6+ had the greatest effect on
cell viability, and Cr3+ the least. The concentration above which there
was a reduction in osteoblast viability was 100 μM (pb0.001) for Co2+,
10 μM for Cr6+ (pb0.0001), and 450 μM for Cr3+ (pb0.0001). The ion
concentration at which osteoblast viability was reduced by 50% (IC50
value), calculated by logistic curve ﬁtting, was 135 μM for Co2+, and
2.2 μM for Cr6+. No IC50 was calculated for Cr3+ as 50% inhibition was
not achieved over the clinical concentration range examined.
Effect of chronic exposure to metal ions on osteoblast viability and
function
Osteoblast proliferation over 13 days was not affected bymetal ion
concentrations of Co2+ or Cr3+ up to 5 μM (Fig. 2A). However, Cr6+ at
1 and 5 μM reduced osteoblast proliferation over 13 days exposure
(pb0.05 and pb0.0001 respectively). These concentrations of Cr6+
had had no effect on short-term osteoblast proliferation.
ALP activity was reduced over 13 days exposure to all metal ions at
100 μM(pb0.001 for Co2+; pb0.0001 for 135 and175 μMmeasuredCr3+
and Cr6+, respectively: Fig. 2B). In addition, Cr6+ exposure also reduced
ALP activity to undetectable levels at concentrations of 10 μM and 1 μM(pb0.05 and pb0.0001, respectively). When ALP activity was corrected
for cell number using DNA content, only Cr6+ reduced ALP activity at the
cellular level (10 μM=pb0.05 and 100 μM=pb0.001). Thus, the
suppressed osteoblast activity was largely a function of reduced cell
number rather than reduced activity per cell. Mineralisation activity,
measured by Alizarin red staining after 21-days culture in osteogenic
medium, was reduced with all metal ion treatments at 100 μM
(pb0.0001, Fig. 2C). Cr6+ at 10 μM also reduced mineralisation activity
(pb0.0001).
Effect of Co2+, Cr3+, and Cr6+ on osteoclastogenesis and resorption
Treatment with Co2+ ions had no effect on osteoclast number from
0.01 μM up to approximately 1 μM (Fig. 3A). The IC50 for Co2+ was
12 μM, and 200 μM reduced the number of TRAP positive osteoclasts
to near zero (pb0.0001). Total resorption followed a slightly different
pattern, with a transient rise in resorption in the sub-micromolar
range (EC50=0.4 μM), followed by complete suppression of resorption
at 200 μM(Fig. 3B and 4A-C, Pb0.001). Treatmentwith Cr3+ resulted in
a biphasic response pattern for both osteoclast number and resorption
(Figs. 3A–B and 4D–F), with concentrations of up to approximately
0.1 μM resulting on increased number (EC50=0.14 μM) and resorption
(EC50=0.27 μM). Above this concentration osteoclast number returned
to physiological baseline and resorption declined to zero at [Cr3+=
200 μM, pb0.001] (IC50 50 μM). Cr6+ ions had the greatest inhibitory
effect on the formation of functional osteoclasts. Increasing Cr6+
resulted in a reduction in the number of osteoclasts (IC50=0.37 μM)
and total resorption (IC50=0.30 μM), (Figs. 3A–B and 4G–I, pb0.0001
for 1 μM to 100 μM).
Effect of Co2+, Cr3+, and Cr6+ on mature, active osteoclasts
To determine the effects of metal ions onmature, fully functional and
active human osteoclasts, human monocytes were isolated, settled onto
dentine disks and cultured as above but in the absence of metal ions to
allow the fusion cells and formationof osteoclasts. The onset of resorption
Fig. 2. Effect of metal ions on osteoblast function. SaOS-2 cells were cultured for 13 days
after which time MTS assay was performed to assess proliferation (A) and ALP activity
measured (B). Mineralisation was assessed in cells cultured in osteogenic medium in the
presence of metal ions for 3 weeks (C). n=3–6 wells per experiment, 3 replicate
experiments. apb0.05, bpb0.01, cpb0.001. (*spectroscopy measured concentrations were
100 μM for Co2+, 125 μM for Cr3+, and 175 μM for Cr6+). Line within boxes indicates
median, boxes represent interquartile range, and whiskers are range.
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daily from day 10 and once resorption had been detected (typically after
14 days), the osteoclast culture medium was then replaced to include
0.01 μM to 200 μM Co2+ and Cr3+ and 0.01 μM to 100 μM Cr6+ ions for
the last 7 days of culture. The pattern of response for Co2+ and Cr3+ was
different to that seen for newly forming osteoclasts in that no transient
increase in cell number or activity was found, and that the inhibitory
effects of all ions were seen at a lower ion concentration. Seven days
treatment with Co2+ ions ≥10 μM reduced mature osteoclast number
(IC50=5.4 μM(pb0.001, Fig. 3C). Total amount of resorptionperdiskwas
only reduced at the high (200 μM) concentration (pb0.0001 and
pb0.001, Figs. 3D and 4J–L). Treatment with Cr3+ ions reduced mature
osteoclast number and resorption per disk, but only at the 200 μM dose
(pb0.05, Figs. 3C–D and 4M–O, IC50 for osteoclast number=221 μMand
IC50 for resorption per disk=77 μM). No trend towards increased
osteoclast number or resorption was seen for mature osteoclasts at the
lower Cr3+ concentration range. Cr6+ ions had the greatest effect on
osteoclast number and resorption. Cr6+ at concentration≥10 μMcaused
a reduction in osteoclast number and resorption per disk (pb0.01 allanalyses, Figs. 3C–D and 4P–R, IC50 for osteoclast number=1.8 μM and
IC50 for resorption per disk=3.9 μM).
Discussion
In this study we examined the effect of chronic exposure of human
osteoblast and primary human osteoclast cells to Co and Cr ions at
concentrations including the clinically equivalent range deﬁned by
previous reports of measured metal levels in the serum and hip
synovial ﬂuid taken from patients after MOMHR. We found that ions
of both metals affected osteoblast and osteoclast cell proliferation and
function. These effects were greatest for Cr6+, then Co2+, with Cr3+
showing the least effect. The observed responses also varied with
metal ion concentration, cell type and cell maturity.
Our ﬁndings are consistent with in-vitro studies using animal cells
that supra-physiological concentrations of cobalt and chromium ions
induce apoptosis in human osteoblast-like cells in-vitro in a dose-
dependent manner [12], and suppress osteoblast synthetic function
[11,21,22]. Our dose-ranging data suggest that chronic exposure to
Co2+ or Cr3+ do not have a major effect on cell viability or synthetic
function at concentrations equivalent to those metal levels found
in serum or synovial ﬂuid in patients after MOMHR, whilst exposure
to Cr6+ has a profound effect on cell viability at concentrations
equivalent to the serum chromium range after MOMHR.
In contrast, our data suggest that an effect of Co and Cr on human
primary osteoclasts occurs within the clinically observed concentra-
tion range and varies with cell maturity. At systemic levels these ions
may have a mild stimulatory effect on developing osteoclasts, but at
higher concentrations and in mature osteoclasts their effect is
inhibitory. The reason for this difference might be explained by the
substrate resorbing activity of the exposed cell, as mature resorbing
osteoclasts may accumulate more intracellular metal ions through
phagocytic activity versus developing osteoclasts, and thus demon-
strate a greater toxic effect due to greater internalisation of the metal.
In support of the increased resorption transient seen in the serum
range, Patntirapong et al. have shown that cobalt ions in solution or
incorporated into calcium phosphate coated plastic at clinically-
relevant concentrations increase murine osteoclast differentiation
and resorption in-vitro[23]. Whilst cobalt ions do not localise to bone,
chromium salts do have an afﬁnity for bone [24], being trapped in the
bone matrix, and thus levels in the bone microenvironment may
exceed those found in serum. Albrecht et al. have also suggested a
possible indirect route for osteoclast activation in response to metal
ions, showing that exposure of human peripheral blood mononuclear
cells to Co2+ ions in-vitro results in upregulation of IL-1α, IL-1β, and
IL-6 expression, that may in turn increase osteoclast birth rate and
resorption [25].
Differences in the cellular responses to Co2+, Cr3+, and Cr6+ are
likely complex, with several mechanisms operating. Co2+ and Cr6+
ion complexes are highly soluble and readily cross cell membranes via
the anion transporter, whilst Cr3+ complexes are less soluble at
physiological pH and cell membrane permeability to Cr3+ is low [26].
These physico-chemical characteristics may explain, in part, the lower
toxicity of Cr3+ relative to the other ions to both osteoblasts and
osteoclasts. The high toxicity of Cr6+ may be explained by its rapid
transport across cell membranes and subsequent reduction to Cr3+
within the cell by glutathione resulting in an increase in oxidative
stress leading to cell death [27].
It is currently unclear which chromium species are released from
prosthesis surfaces after MOMHR. Metal ion release as a result of
corrosion, distinct to that arising from the process of wear, has been
identiﬁed as a signiﬁcant contributor to systemic metal release after
MOMHR [7,28]. Merritt and Brown have shown that Cr6+ is released
during the corrosionof orthopaedic implants and is present systemically
in-vivo [29]. However, De Flora et al. have observed that circulating
whole blood has a capacity to sequester and reduce approximately
Fig. 3. Effect of metal ions on human osteoclasts. A–B) Osteoclast formation. Monocytes were isolated from human peripheral blood, settled onto dentine disks then culturedwithM-CSF
and RANKL plus either Co2+, Cr3+ or Cr6+ ions for 21 days. C–D)Mature osteoclasts. Cells were culturedwithM-CSF and RANKL for 14 days prior to the addition ofmetal ions (C–D). Cells
were ﬁxed and stained for TRAP with the number of osteoclasts and amount of resorption per dentine disk determined. n=5 wells per experiment, 3 replicate experiments. *pb0.05,
**pb0.01, ***pb0.001. Logistic curve ﬁtting was used to calculate the approximate EC50 and IC50 values.
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MOMHR bearings. Thus, bone cells in the prosthesis microenvironment
may be subject to released Cr6+, and our data show that at clinically
relevant levels this would be highly toxic to local osteoblasts and
osteoclasts. A recent speciation study of chromium complexes by
microfocus x-ray spectroscopy using a synchrotron beam in retrieved
tissues around failed MOMHR prostheses showed chromium is present
mainly as chromium(III) phosphate [31].However, asCr3+has poor cell
membrane permeability, its presencemay arguably be accounted for byits entering the cell as Cr6+ then being reduced to Cr3+, and giving rise
to the necrotic lesions for which the biopsies were taken.
Our observation of the toxicity of Co2+ to osteoclast cells at
synovial ﬂuid levels and to osteoblasts at concentrations 3–5 times
that found in local tissues after MOMHR may occur through a similar
mechanism to that observed in previous studies of lung toxicology.
High concentrations of Co2+ are thought to induce cell damage by
stabilising hypoxia inducible factors (HIF) that bind to DNA and
initiate hypoxia-related gene expression and are normally degraded
Fig. 4.Metal ions and osteoclast number and dentine resorption. Peripheral blood mononuclear cells from healthy donors were cultured on dentine slices in recombinant M-CSF and
RANKL-supplemented medium to generate multinucleated-osteoclasts. At day 21, dentine slices were ﬁxed in 10% buffered formalin, stained for tartrate-resistant acid phosphatase
(TRAP) and counterstained with Gill's haematoxylin. In “A,” the stars correspond to TRAP positive osteoclasts and the arrows point to the resorption pits. Metal ions were introduced
in the culture at day 3 (for A–I) at the indicated concentrations. For J–R, metal ions were introduced once resorption was observed, generally day 14, indicating mature osteoclasts.
Typical ﬁelds of view of cells following treatment; A–C and J–L treated with Co2+, D–F and M–O with Cr3+, G-I and P–R with Cr6+. Scale bar 200 μm.
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723R.E. Andrews et al. / Bone 49 (2011) 717–723under normal oxygen tensions, resulting in HIF pathway activation
and cellular apoptosis [32,33].
Our observations that Co and Cr ions at clinically identiﬁed levels
after MOMHR have several clinical implications for local bone health.
Suppressed osteoblast activity may explain early aseptic loosening
as a failure of primary osseo-integration. In support of this concept,
Long et al. have reported a 15% failure rate for the Durom acetabular
prosthesis in 207 hips within 2 years following implantation [34].
In all cases but 1 aseptic loosening of the prosthesis was the mode
of failure, and in 13 prostheses examined in detail at retrieval, all
showed failure of osseo-integration of bone onto the ﬁxation surface.
Femoral neck narrowing has commonly been reported after MOMHR
and may contribute to fracture risk [35]. It has been suggested that
narrowing occurs as a result of elevated hydrostatic ﬂuid pressures in
these patients, however, and alternative mechanism may be through
osteoclast activation at the bone surface due to elevated metal levels.
In support of this increased osteoclast numbers have been identiﬁed
histologically on periosteal surfaces in fracture cases with femoral
neck narrowing after MOMHR (Pat Campbell, personal communica-
tion). At a systemic bone health level, our data suggest that metal ions
release may be sufﬁcient to impact on osteoclast cell activity and
number that in turn may affect bone mass and remodelling. The long
term implication of systemic metal release after MOMHR for systemic
bone health remains to be elucidated.
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